Brian C. Joondeph

Safety and efficacy of ixoberogene soroparvovec in neovascular age-related macular degeneration in the United States (OPTIC): a prospective, two-year, multicentre phase 1 study

C. Regillo, C. Wykoff, D. Pieramici, 2023, EClinicalMedicine.